CN101730541B - 作为传染性病原体或毒素相关疾病的疫苗佐剂的细胞外基质材料 - Google Patents

作为传染性病原体或毒素相关疾病的疫苗佐剂的细胞外基质材料 Download PDF

Info

Publication number
CN101730541B
CN101730541B CN200780052437.8A CN200780052437A CN101730541B CN 101730541 B CN101730541 B CN 101730541B CN 200780052437 A CN200780052437 A CN 200780052437A CN 101730541 B CN101730541 B CN 101730541B
Authority
CN
China
Prior art keywords
infectious agent
vaccine
adjuvant
interest
infectious
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780052437.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN101730541A (zh
Inventor
马克·A·苏科
威廉·R·沃尔特
保罗·J·哈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cook Biotechnology
University of Notre Dame
Original Assignee
Cook Biotechnology
University of Notre Dame
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cook Biotechnology, University of Notre Dame filed Critical Cook Biotechnology
Publication of CN101730541A publication Critical patent/CN101730541A/zh
Application granted granted Critical
Publication of CN101730541B publication Critical patent/CN101730541B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN200780052437.8A 2007-01-30 2007-05-25 作为传染性病原体或毒素相关疾病的疫苗佐剂的细胞外基质材料 Expired - Fee Related CN101730541B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/699,448 US9308252B2 (en) 2005-10-27 2007-01-30 Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US11/699,448 2007-01-30
PCT/US2007/069727 WO2008094276A1 (en) 2007-01-30 2007-05-25 Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins

Publications (2)

Publication Number Publication Date
CN101730541A CN101730541A (zh) 2010-06-09
CN101730541B true CN101730541B (zh) 2014-03-05

Family

ID=39359947

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780052437.8A Expired - Fee Related CN101730541B (zh) 2007-01-30 2007-05-25 作为传染性病原体或毒素相关疾病的疫苗佐剂的细胞外基质材料

Country Status (6)

Country Link
US (3) US9308252B2 (cg-RX-API-DMAC7.html)
EP (1) EP2114444B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010516763A (cg-RX-API-DMAC7.html)
CN (1) CN101730541B (cg-RX-API-DMAC7.html)
AU (1) AU2007345673A1 (cg-RX-API-DMAC7.html)
WO (2) WO2008094276A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2697373C (en) 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
WO2009085355A2 (en) 2007-10-01 2009-07-09 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
WO2010078478A1 (en) 2008-12-31 2010-07-08 Cook Biotech Incorporated Tissue adjuvants and medical products including the same
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
ES2626488T3 (es) 2011-07-19 2017-07-25 Wave Life Sciences Pte. Ltd. Procedimientos para la síntesis de ácidos nucleicos funcionalizados
CA3207612A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
BR112015000723A2 (pt) * 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
ES2940887T3 (es) 2012-07-13 2023-05-12 Wave Life Sciences Ltd Método de preparación de oligonucleótidos quirales
CN103110943B (zh) * 2013-03-11 2014-11-26 浙江普康生物技术股份有限公司 一种可替代氢氧化铝的新型疫苗佐剂
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
EP3294448A4 (en) 2015-05-14 2018-12-12 Longhorn Vaccines and Diagnostics, LLC Rapid methods for the extraction of nucleic acids from biological samples
CN106860861B (zh) * 2017-03-03 2020-11-03 北京博辉瑞进生物科技有限公司 一种免疫增强组合物、制备方法及其应用
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
CA3176187A1 (en) * 2020-04-22 2021-10-28 Clay Fette Compositions comprising extracellular material with antiviral activity and uses thereof
US12403189B2 (en) 2020-10-20 2025-09-02 Longhorn Vaccines And Diagnostics, Llc Immunogenic antigens
US20250375512A1 (en) * 2022-06-24 2025-12-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of matrix bound vesicles (mbv) as vaccine adjuvants

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2172903A (en) * 1937-09-24 1939-09-12 Paul M Charping Electric lighting system
US3346401A (en) * 1963-12-12 1967-10-10 Council Scient Ind Res Processing of raw intestines
AT261800B (de) * 1966-08-22 1968-05-10 Braun Internat Gmbh B Verfahren zur Herstellung von röhrenförmigen, glatten bzw. mit einem Gewinde versehenen Gewebe-Blutgefäß-Prothesen
US3810473A (en) * 1972-12-04 1974-05-14 Avicon Inc Liquid-laid, non-woven, fibrous collagen derived surgical web having hemostatic and wound sealing properties
US4578067A (en) * 1982-04-12 1986-03-25 Alcon (Puerto Rico) Inc. Hemostatic-adhesive, collagen dressing for severed biological surfaces
US4502159A (en) * 1982-08-12 1985-03-05 Shiley Incorporated Tubular prostheses prepared from pericardial tissue
DE3850956D1 (de) * 1988-03-11 1994-09-08 Chemokol G B R Ing Buero Fuer Verfahren zur Herstellung von Kollagenmembranen für Hämostase, Wundbehandlung und Implantate.
US4956178A (en) * 1988-07-11 1990-09-11 Purdue Research Foundation Tissue graft composition
US4902508A (en) * 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5336616A (en) * 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
US6120991A (en) * 1990-10-30 2000-09-19 Fred Hutchinson Cancer Research Center Epiligrin, an epithelial ligand for integrins
US5281422A (en) * 1991-09-24 1994-01-25 Purdue Research Foundation Graft for promoting autogenous tissue growth
US5507810A (en) * 1991-10-07 1996-04-16 Osteotech, Inc. Processing of fibrous connective tissue
US5437287A (en) * 1992-08-17 1995-08-01 Carbomedics, Inc. Sterilization of tissue implants using iodine
US5275826A (en) * 1992-11-13 1994-01-04 Purdue Research Foundation Fluidized intestinal submucosa and its use as an injectable tissue graft
US5352463A (en) * 1992-11-13 1994-10-04 Badylak Steven F Tissue graft for surgical reconstruction of a collagenous meniscus and method therefor
US5480424A (en) * 1993-11-01 1996-01-02 Cox; James L. Heart valve replacement using flexible tubes
US5460962A (en) * 1994-01-04 1995-10-24 Organogenesis Inc. Peracetic acid sterilization of collagen or collagenous tissue
US6156305A (en) * 1994-07-08 2000-12-05 Baxter International Inc. Implanted tumor cells for the prevention and treatment of cancer
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5695998A (en) * 1995-02-10 1997-12-09 Purdue Research Foundation Submucosa as a growth substrate for islet cells
US6207147B1 (en) * 1996-10-11 2001-03-27 The Regents Of The University Of California Cancer immunotherapy using tumor cells combined with mixed lymphocytes
US7361332B2 (en) * 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US5733337A (en) * 1995-04-07 1998-03-31 Organogenesis, Inc. Tissue repair fabric
US5554389A (en) * 1995-04-07 1996-09-10 Purdue Research Foundation Urinary bladder submucosa derived tissue graft
WO1996031232A1 (en) * 1995-04-07 1996-10-10 Purdue Research Foundation Tissue graft and method for urinary bladder reconstruction
US6406689B1 (en) * 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
NZ331960A (en) 1996-04-03 1999-10-28 Rogosin Inst Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
EP1955721B1 (en) * 1996-08-23 2014-10-29 Cook Biotech, Inc. Collagen-based graft prosthesis
US5782914A (en) * 1996-11-29 1998-07-21 Bio-Vascular, Inc. Method for preparing heterogeneous tissue grafts
ES2227833T3 (es) * 1997-05-12 2005-04-01 Aphton Corporation Composiciones inmunogenicas para el receptor cck-b/gastrina y metodos para el tratamiento de tumores.
AU743808B2 (en) * 1998-02-27 2002-02-07 Purdue Research Foundation Submucosa gel compositions
DE19916085A1 (de) * 1998-10-28 2000-05-04 Sonntag Hans Guenther Verfahren zur Herstellung eines antiviralen Mittels
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
DE60031100T2 (de) * 1999-03-16 2007-03-08 Thomas Jefferson University Hapten modifizierte tumorzellen und verfahren zur herstellung und deren verwendung
JP2000264900A (ja) * 1999-03-16 2000-09-26 Hisamitsu Pharmaceut Co Inc 新規生理活性ペプチド
US6105775A (en) * 1999-04-20 2000-08-22 Pakon, Inc. Sleeving system for photographic film negatives
CA2370643A1 (en) * 1999-04-26 2000-11-02 Emory University Noscapine derivatives as adjuvant compositions and methods of use thereof
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
IT1318663B1 (it) * 2000-08-02 2003-08-27 Mediolanum Farmaceutici Srl Membrane di collagene a due facce di cui una organizzata a livellomacromolecolare.
JP4426285B2 (ja) * 2001-06-28 2010-03-03 クック・バイオテック・インコーポレーテッド 腎被膜コラーゲンを含有する移植片プロテーゼ用具
US6986739B2 (en) * 2001-08-23 2006-01-17 Sciperio, Inc. Architecture tool and methods of use
WO2003100034A2 (en) 2002-03-18 2003-12-04 Sciperio, Inc. Dentritic cell nodes
FR2842822B1 (fr) * 2002-07-26 2004-10-01 Roussy Inst Gustave Procede de preparation d'une matrice extracellulaire et son utilisation pour la culture de cellules tumorales
WO2004017866A1 (en) * 2002-08-20 2004-03-04 Cook Incorporated Stent graft with improved proximal end
US7550004B2 (en) * 2002-08-20 2009-06-23 Cook Biotech Incorporated Endoluminal device with extracellular matrix material and methods
WO2005023321A2 (en) * 2003-09-04 2005-03-17 Cook Biotech Incorporated Extracellular matrix composite materials, and manufacture and use thereof
US8257715B1 (en) * 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
WO2006125055A2 (en) * 2005-05-17 2006-11-23 Cook Incorporated Prosthetic valve devices and methods of making and using such devices
AU2006292203A1 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8778360B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US7545569B2 (en) * 2006-01-13 2009-06-09 Avery Dennison Corporation Optical apparatus with flipped compound prism structures
CA2627364A1 (en) 2007-01-30 2008-07-30 University Of Notre Dame Du Lac Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US9283266B2 (en) 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US8846059B2 (en) * 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Megumu Higaki et al.Collagen minipellet as a controlled release delivery system for tetanus and diphtheria toxoid.《Vaccine》.2001,第19卷第3091－3096页. *
苏琰等.小肠粘膜下层修复组织缺损的应用研究.《国外医学·骨科学分册》.2004,第25卷(第1期),第43-45页. *

Also Published As

Publication number Publication date
WO2008112344A3 (en) 2009-12-30
AU2007345673A1 (en) 2008-08-07
EP2114444A1 (en) 2009-11-11
US9308252B2 (en) 2016-04-12
US20080107665A1 (en) 2008-05-08
US9220770B2 (en) 2015-12-29
CN101730541A (zh) 2010-06-09
WO2008112344A2 (en) 2008-09-18
EP2114444B1 (en) 2014-10-22
US20110076305A1 (en) 2011-03-31
US20100136050A1 (en) 2010-06-03
EP2114444A4 (en) 2010-09-29
JP2010516763A (ja) 2010-05-20
WO2008094276A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
CN101730541B (zh) 作为传染性病原体或毒素相关疾病的疫苗佐剂的细胞外基质材料
Tamura et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine
Clements et al. The global impact of vaccines containing aluminium adjuvants
JP2011190278A (ja) 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方
US9585955B2 (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
Bonanni et al. Vaccine evolution
US8277778B2 (en) Vaccine adjuvants
CA2627364A1 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
CN115996751A (zh) 与离子液体佐剂有关的方法和组合物
WO2022019769A1 (en) Bordetella outer membrane vesicles
JP4530317B2 (ja) 減毒化トキシンを含むワクチン製剤
JP2004508424A (ja) 免疫調節調剤物
JPWO2000023107A1 (ja) 減毒化トキシンを含むワクチン製剤
CA3227550A1 (en) Clostridium chauvoei vaccine and method of making
Bragazzi et al. Vaccine Adjuvants: History, Role, Mechanisms of Action, and Side Effects
Kumar et al. Whole-cell vaccine preparation: Options and perspectives
AU2004235815A1 (en) Vaccinating against infectious diseases using proteosomes
Falkeborn et al. Comparison of the mucosal adjuvant Endocine™ with two well-known adjuvants: Cholera toxin and alum
Iyer et al. An indian perspective of some recent developments in polio, dpt, zika and rotavirus vaccines
Júnior et al. Immunization of Hens 10

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140305

Termination date: 20160525

CF01 Termination of patent right due to non-payment of annual fee